Holly Liptak is an Editorial Assistant for Healio, a publication focused on providing healthcare professionals with the latest news and information in their field. Holly covers a wide range of topics in the medical field, including advancements in cancer treatment, sleep hygiene, and strategies for preventing diseases like hepatitis C.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Holly Liptak's coverage mainly focuses on healthcare and pharmaceuticals, with a strong emphasis on citing data. She would likely be receptive to pitches from experts who can provide in-depth analysis or commentary based on robust data related to developments in cancer treatment, lung cancer, and other medical topics she covers.
Given her focus on specific medical conditions and treatments, Holly may welcome insights from professionals directly involved in the research or treatment of these conditions. However, she might also consider expert opinions that offer broad perspectives across similar areas of healthcare & pharmaceuticals.
While Holly doesn't have a specified geographic focus, it’s important for any outreach to align with global trends and developments within the healthcare and pharmaceutical sphere.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Holly Liptak
A presentation at ASCO Annual Meeting supported the use of first-line axitinib and pembrolizumab in the treatment of patients with advanced renal cell carcinoma.Patients with confirmed stage IV metastatic renal cell carcinoma who had initiated first-line axitinib (Inlyta, Pfizer) and pembrolizumab (Keytruda, Merck) on or after Jan. 1, 2018, to July 31, 2022, from 280 cancer clinics in the U.S.
By: Holly Liptak
Pembrolizumab added to twice weekly gemcitabine plus transurethral muscle-invasive urothelial cancer resection of a bladder tumor and hypofractionated radiation therapy appeared safe for patients with muscle-invasive urothelial cancer.
Research supports an association between sleep and brain health, and suggests that people who have consistent difficulty initiating and staying asleep may be negatively impacted.
By: Hossein Borghaei, Holly Liptak
MADRID — Hossein Borghaei, DO, MS, discussed results from the PAPILLON trial, which combined amivantamab and chemotherapy as first-line treatment for EGFR exon 20 insertion-mutated non-small cell lung cancer, in a video interview.The study was presented at ESMO Congress.
By: Holly Liptak, Mindy Valcarcel, Hossein Borghaei
MADRID — Healio spoke with Hossein Borghaei, DO, MS, about the results of the MARIPOSA-2 trial, which were presented at ESMO Congress.
By: Holly Liptak, Hossein Borghaei, Mindy Valcarcel
MADRID — Hossein Borghaei, DO, MS, discussed results from the ALINA study on ALK -positive non-small cell lung cancer, which were presented at ESMO Congress, in a video interview with Healio.
By: Holly Liptak, Mindy Valcarcel, Hossein Borghaei
MADRID — In this video interview with Healio, Hossein Borghaei, DO, MS, talked about results from the MARIPOSA study presented at ESMO Congress.
By: Holly Liptak
There is a reduction in syringe sharing when methadone providers are spread out near areas with the greatest density of people who inject drugs, according to research presented at The Liver Meeting. Researchers in Chicago established a baseline scenario of spatial access using locations of existing methadone providers in the metropolitan area. The locations of providers were then spatially redistributed based on the densities of the general population and the population of people who inject drugs (PWID) per zip code.
By: Holly Liptak, Heather Biele
Key takeaways: The MD Anderson Cancer Center initiated universal HCV screening for all new outpatients with a focus on patients with solid tumors.
Patients with rheumatoid arthritis may be able to tame their disease progression and inflammation by adopting elements of the Mediterranean diet such as lowering sugar intake and incorporating protein in the form of fish or plant-based sources.
(833) 317-6278 
